secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aptose Biosciences Inc. (APTOF)
CIK:        0000882361
Form:       8-K
Filed at:   2025-08-18T23:59:59+00:00
Accession:  0001171843-25-005463
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aptose reports tuspetinib triplet achieves 90% CR/CRh in newly diagnosed AML Phase 1/2 trial
--------------------------------------------------------------------------------

- 100% CR/CRh at 80 mg and 120 mg TUS doses in combination with VEN+AZA (9/10 subjects).
- 78% MRD-negativity among responders (7/9); 100% MRD-negativity in TP53, RAS, FLT3-ITD subgroups.
- No dose-limiting toxicities or prolonged myelosuppression; enrollment advancing to 160 mg cohort.
- Single non-responder was at 40 mg dose with subtherapeutic TUS exposure; all other patients remain on study.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882361/000117184325005463/0001171843-25-005463-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882361/000117184325005463/f8k_081825.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-005463

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer